Internet Pioneer In...
Health Care: Drugs
Alkermes PLC (ALKS: NASDAQ)
$15.12 -0.50 | -3.20%
06/01/12 - 04:00 PM ET
Latest Dividend:0.00
Latest Dividend Yield:0.00%
Dividend Ex-Date:05/15/00
Price Earnings Ratio:n/a
Price Earnings Comparisons:
| ALKS | Sector Avg. | S&P 500 |
|---|---|---|
| n/a | 0.00 | 17.70 |
Price Performance History (% change):
| 3 Mo | 1 Yr | 3 Yr |
|---|---|---|
| -9.62 | 11.30 | 18.87 |
| GROWTH | 12 Mo | 3 Yr | CAGR |
|---|---|---|---|
| Revenue | 108.90 | 0.19 | 0.06 |
| Net Income | -1.87 | 0.00 | |
| EPS | -1.72 | 0.00 |
Earnings for ALKS:
| EBITDA | 5.40M |
| REVENUE | 389.98M |
Average Earnings Estimates
| Qtr (06/12) | Qtr (09/12) | FY (03/13) | FY (03/14) | |
|---|---|---|---|---|
| Average Estimate | $-0.07 | $-0.07 | $-0.23 | $0.01 |
| Number of Analysts | 9 | 8 | 9 | 10 |
| High Estimate | $-0.04 | $-0.03 | $-0.11 | $0.45 |
| Low Estimate | $-0.11 | $-0.13 | $-0.46 | $-0.45 |
| Prior Year | $-0.04 | $-0.14 | $-0.59 | $-0.23 |
| Growth Rate (Year over Year) | -75.00% | 51.79% | 60.83% | 106.06% |
Portfolios with ALKS
- Portfolio NameUser Type
- ContributorEarnings Short Squeeze Play...
- ContributorStocks With Big Insider Buy...
- UserInvestments
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- ContributorBreakout Stocks Of The Week...
- Usergterryburns
- Usermitetwo Portfolio 1
- ContributorBreakout Stocks Of The Week...
- Contributor10 Biotech Stocks Facing FD...
Latest ALKS Headlines from TheStreet
- Cramer's 'Mad Money' Recap: Housing Comeback 05.10.12 | 08:05 pm
- 5 Stocks Insiders Love Right Now 05.02.12 | 11:05 am
- 8 Stocks Rising on Monster Volume 03.28.12 | 12:03 pm
- Insiders Trading TZYM, ALKS, CAKE 03.15.12 | 08:03 am
- The Curse of Amylin's Diabetes Drug Approval 02.06.12 | 08:02 am
- PharMerica, Amylin: After-Hours Trading 01.27.12 | 06:01 pm
- Third Time's The Charm for Approval of Amylin Diabetes Drug 01.27.12 | 03:01 pm
- 7 Stocks Rising on Huge Volume 01.25.12 | 02:01 pm
- UBS: 6 Specialty Pharma Picks to Watch 01.21.12 | 07:01 am
- Biotech Lessons Learned From JPM 2012 01.13.12 | 06:01 am
Press Releases for ALKS
- Alkermes’ Corporate Presentation To Be Webcast At Two Upcoming Conferences - Business Wire 05.31.12 | 07:05 am
- Alkermes Announces Results From Phase 2 Study Of ALKS 37 For Treatment Of Opioid-Induced Constipation - Business Wire 05.30.12 | 04:05 pm
- Alkermes Presents Positive Clinical Data Of ALKS 5461 At 52nd Annual New Clinical Drug Evaluation Unit Meeting - Business Wire 05.29.12 | 04:05 pm
- Alkermes Plc Completes Secondary Offering Of 24,150,000 Ordinary Shares Held By Elan - Business Wire 03.13.12 | 11:03 am
- Alkermes Plc Prices Secondary Offering Of 21,000,000 Ordinary Shares Held By Elan - Business Wire 03.08.12 | 09:03 am
- Alkermes Plc Announces A Secondary Offering Of 13,900,000 Ordinary Shares Held By Elan - Business Wire 03.07.12 | 04:03 pm
- Alkermes Appoints Mark Stejbach As Chief Commercial Officer - Business Wire 03.05.12 | 07:03 am
- Alkermes’ Corporate Presentation To Be Webcast At The Cowen & Company 32nd Annual Health Care Conference - Business Wire 02.27.12 | 04:02 pm
- Alkermes Files Resale Shelf Registration In Connection With Elan Shareholder Agreement - Business Wire 02.16.12 | 04:02 pm
- BYDUREONâ¢, First And Only Once-Weekly Type 2 Diabetes Treatment, Now Available In U.S. Pharmacies - PR Newswire 02.13.12 | 08:02 am
Partner Headlines for ALKS
- Healthcare Biz Recap: Teva's Counterfeit Problem, Hopes for Bristol-Myers - Wall St. Cheat Sheet 05.30.12 | 07:05 am
- Alkermes Earnings Call Insights: Adjusted EBITDA, VIVITROL - Wall St. Cheat Sheet 05.29.12 | 01:05 pm
- 9 High-Liquidity Mid Caps Poised For Growth - Seeking Alpha 05.28.12 | 08:05 am
- Long Undervalued, Is Alkermes Still A Bargain? - Seeking Alpha 03.30.12 | 09:03 am
- Kinetics Hedge Fund's Top Undervalued Picks - Seeking Alpha 03.23.12 | 05:03 pm
- Elan Sells 76% Stake in Alkermes - Analyst Blog - Zacks 03.16.12 | 05:03 pm
- Alkermes Announces a Secondary Offering of 13,900,000 Ordinary Shares Held by Elan - Benzinga 03.07.12 | 04:03 pm
- Bydureon Physician Survey: Results Yield Insight Into Launch Trajectory - Seeking Alpha 02.22.12 | 08:02 am
- The Zacks Analyst Blog Highlights: Charles Schwab, E*TRADE Financial, TD Ameritrade Holding, Amylin Pharmaceuticals and Alkermes plc - Press Releases - Zacks 02.16.12 | 09:02 am
- Analyzing Friday's Noteworthy Insider Buys And Sells - Seeking Alpha 02.12.12 | 07:02 am
